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ABSTRACT 
Biofilms, or colonies of uropathogen growing on the surface of indwelling medical devices, can inflict obstinate 
or recurring infection, thought-provoking antimicrobial therapy.  This prospective analysis included of 227 
patients with indwelling urinary catheters were analyzed for biofilm formation and antibiogram susceptibility, 
59.4% were males and 40.6% were females. Ensuing phenotypic identification, antibiotic sensitivity test was 
performed by modified Kirby–Bauer disc diffusion method following CLSI guidelines; MDR isolates were 
identified according to the combined guidelines of  the Centers for Disease Control and Prevention (CDC). 
Biofilm-forming uropathogens were detected by the tissue culture plate (TCA) method. The predominant 
uropathogen in catheter-associated UTIs (CAUTIs) was Escherichia coli 46.3%, followed by Klebsiella 
pneumonia 18.5%, Pseudomonas aeruginosa 11.9%, Proteus mirabilis 7%, Staphylococcus coagulase negative 
5.7,  Staphylococcus aureus 4.8%, Enterobacter spp. 4.4%, Enterococcus faecalis 1.3%.  The total rate of 
biofilm producer bacteria was 49.3% (21.1% high producers, 28.2% modrate producers). Prime biofilm 
producers were Escherichia coli 60%  with OR=8.6 (p=0.002), followed by Klebsiella pneumoniae 57.1% with 
OR=10.1 (p=0.002), and Pseudomonas aeruginosa 37% with OR=6.6 (p=0.02). The biofilm producers bacteria 
were associated with >65year patients (OR=5.4, p>0.001), pre-UTI (OR=2.4,p<0.001), long duration of 
catheterization (OR=15.3, p<0.001), and diabetic mellitus (OR=3.5, p<0.001). Multidrug resistance associated 
with biofilm producers were greater than biofilm non-producers.  Gram-negative biofilm producers found 100%, 
100%, 88.6%, 82.9%, 81.9%, 80.9%, and 72.4%, 40%, 33% resistant to ampicillin , amoxyclave, cotrimoxazole, 
 ceftraxone, naldixic acid, cipreofloxacin, cefotaxime , nitrofurantoin and amikacin respectively. Gram-positive 
biofilm producers, however, were found 85.7%, 85.7%, 71.4%, 71.4%, 57.1% and 42.9% resistant to penicillin, 
erythromycin, cotrimoxazole, gentamycin, norofloxacin, and nitrofurantoin respectively. In conclusion, a high 
antimicrobial resistance was observed in biofilm producers than non-biofilm producers. Of recommended 
antimicrobial therapies for CAUTIs, ampicillin and amoxicillin-clavulanate were the least active antibiotics, 
whereas  imipenem and amikacin were found as the most effectual for gram-negative biofilm producer. 
Likewise, penicillin and erythromycin were the least active antibiotics, whereas vancomycin, and rifampicin 
were found as the most effective antibiotic for Gram-positive biofilm producer.  
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INTRODUCTION 
Biofilms have been found to be involved in a wide range of microbial infections in the body, by one estimate 
80% of all infections.
1
 Infectious processes in which biofilms are involved include common problems such as 
bacterial vaginosis, urinary tract infections, catheter infections, middle ear infections, and dental plaque 
formation 
2
, gingivitis and contact lenses, 
3 
fatal processes such as endocarditis, and inflammation in cystic 
fibrosis , and permanent indwelling devices like joint prostheses, heart valves, and intervertebral disc.
4,5,6
   Of 
nearly 40 percent of all healthcare related infections, urinary tract infections (UTIs) are the leading cause of 
infection. Out of this, a massive proportion, 80%, involves urinary tract infections associated with catheters 
(CUTI) 
7, 6
. Urinary catheters are used routinely in urinary tract practice; despite the progress made in the design 
and materials used, urinary tract infection remains the main obstacles, due to the contamination of these 
residential devices
8,5
. Roughly, between 12 to 16% of hospital inpatient adults have urinary tract indwelling 
catheter, however, it is known to be associated with high morbidity rates, high mortality rates, increased length 
of hospital stay, and the increase in the cost of treatment 
6-9
. Furthermore, biofilm producers associated with 
catheters, preceding drug resistance, and thought-provoking infection control measures have been reported in 
previous studies, which raises concern on CAUTIs and biofilm producers in hospital environments 
10,11
.  
A biofilm contains any syntrophic consortium of microorganisms in which cells attach to each other and often as 
well to a surface.
11,13
 These adherent cells become embedded within a slimy extracellular matrix that is 
composed of extracellular polymeric substances (EPS).
12,13
 The cells within the biofilm produce the EPS 
components, which are typically a polymeric conglomeration of extracellular  polysaccharides,  proteins,  lipids 
 and  DNA.
12-14
   
   The extracellular matrix facilitates communications among the cells through biochemical signals—acyl-
homoserine lactone in Gram-negative bacteria and oligopeptides in Gram-positive bacteria—in a phenomenon 
  
 
called as quorum sensing
15
. Biofilms are not just bacterial slime layers but biological systems; the bacteria 
organize themselves into a coordinated functional community 
16
. The matrix not only impedes the pathogen 
against the host's defense, but also attributes the antimicrobial resistance, through the subordinating antibiotic 
penetration, horizontal transmission of plasmid-associated drug-resistant gene, and altered 
microenvironment
15,17
. 
   In this situation, early detection of biofilm producers is crucial to reduce the irrational burden of antimicrobials 
resulting from antimicrobial resistance in the patient; thus, it will be helpful in control of infection associated 
with devices in medical fields. The rationale for the current study was to clarify bacterial etiology, highlight the 
resistance patterns associated with biofilm producing bacteria and establish appropriate antimicrobial therapy 
against biofilm producers in people with CAUTIs. 
MATERIAL AND METHODS 
 Study Design 
The cross-sectional study was conducted at the Department of bacteriology, the National Center of Public Health 
Laboratories (NCPHL) and Al-Thorah Hospitals in Ibb city, Ministry of Health and Population, Yemen, over a 
period of 12 months. The study hospital is a referral centre with medical, surgical, gynecological, pediatric, 
geriatric, and other specialties. 
 Inclusion and Exclusion Criteria.  
Urine specimen was included from all catheter patients regardless of gender and age between 12 and 65 years 
who met the CAUTI criteria in the study. However, non-catheterized patients who were cared for in a ward or 
previously under antimicrobial treatment before inserting the catheter were excluded. Also more than two types 
of organism grown from the clinical sample, were considered as contaminated and consequently, excluded from 
the study. 
Data collection 
Data were collected through a predetermined questionnaire. Data including patient demographic data, clinical 
information, biofilm formation and antibiotic susceptibility; risk factors of biofilm formation, and other 
laboratory results. 
 Laboratory Methods 
CAUTI is defined using a combination of signs, clinical symptoms, and laboratory standards as described by 
Stamm
8
. A total of 335 urine samples from catheterized patient's admitted to the hospital were treated almost 
quantitatively by inoculating 0.001 ml of the sample (using a titrated wire loop) on the Cystine Lactose 
Electrolyte Deficiency (CLED) agar to isolate and identify uropathogens [8]. Following the inoculation, the 
plates were incubated for 24 hours at 37°C in an aerobic atmosphere. The growth of a single organism with a 
count of ≥102 colony forming units (CFU)/ml was considered to represent as CAUTIs (positive samples counted 
227) and was identified using appropriate routine identification methods including colony morphology, Gram 
stain, and an in-house set of biochemical tests
18
. 
 Antimicrobial SusceptibilityTesting 
 The susceptibility of bacterial isolates against recommended antibiotics was tested by the modified Kirby–Bauer 
disk diffusion method on Mueller Hinton agar (Oxoid) following guidelines of Clinical and Laboratory 
Standards Institute (CLSI) 
19
. Antibiotics that were tested in our study include amoxycillin clavulanate (amc 
20/10 μg), ampicillin (amp 10 μg), amikacin (ak 30 μg),  cefuroxime (cfm 30 μg), ciprofloxacin (cip 5 μg),  
cotrimoxazole (cot 25 μg),  gentamicin (gen 10 μg), imipenem (imp 10 μg),  nitrofurantion (300 μg), nalidixic 
acid (NA 30 μg)  penicillin  (P 25 μg), erythromycin (E 15 μg), norofloxacin (Nor 10 μg), rifampicin (RA 5 μg) 
and vancomycin (VAN 30 μg) (Oxoid). 
Biofilm production detection 
The detection of biofilm was done by tissue culture method/microtiter plate method (TCA)
20, 21
. The bacterial 
isolates from fresh agar plates were inoculated in 2 ml of BHI broth and incubated for 24 h at 37°C. The cultures 
were then diluted 1 : 40 with fresh medium (BHI broth supplemented with 1% glucose); 200 μl of the sample 
was dispensed in the individual microtitration plate and incubated further 24 h at 37°C. With a gentle tapping, 
the content was removed further with a subsequent washing with phosphate buffer saline (pH 7.2) three times to 
remove free floating sessile bacteria. The adherent bacteria, biofilm producer, were fixed with sodium acetate 
(2%) and stained with crystal violet (0.1% w/v) for 10–15 min. The unbound crystal violet solution was removed 
with a triplicate washing with PBS, and the plate, then, was kept for drying. Finally, all wells were filled with 
200 μl ethanol (95%) to release dye from the well and Optical Density (OD) was taken at the wavelength of 630 
nm.  OD value of each test strain and negative control were calculated, and OD cutoff values (ODc) were 
assessed as described previously
21
. 
 Data Analysis 
  
 
Personal, clinical and laboratory data were obtained from each subject and recorded into a pre-designed 
questionnaire, then the data were statistically analyzed by a software version for statistical significance (Epi Info 
version 6, CDC, Atlanta, USA). First rates were calculated, then from two-by-two tables, the odds ratios were 
calculated and P-value was determined using the uncorrected chi square test. Fisher’s exact test was used for the 
small expected cell sizes with a two-tailed probability value. 
Ethical approval  
We obtained written consent from all cases. Assent was taken from participants before collecting the specimens. 
The study proposal was evaluated and approved by the Ethics Committee of Faculty of Medicine and Health 
Sciences, Sana’a University. 
RESULTS 
The study results are illustrated in 8 tables. Out of 227 culture positive cases, Gram negative organisms were 
predominant (88.1%).  The most organisms caused UTI among catheter patients in this study were belonging to 
Gram negative bacteria (88.1%), while Gram positive isolates only counted 11.9%. The most frequently isolated 
uropathogens was E.coli (46.3%) followed by K.pneumoniae (18.5%) and Pseudomonas aeruginosa (11.9%). 
Finally, the maximum biofilm production in the current study was seen in E. coli where 63 out of the 105 isolates 
(61%) showed biofilm production followed by Klebsiella spp. (57.1%) and Pseudomonas spp. (37.0%). The 
present study showed that the most effective antibiotics against biofilm producing Gram negative isolates was 
imipenem and for Gram positive isolates was vancomycin. The biofilm strains displayed relatively high 
resistance against tested antibiotics than non biofilm producers. Resistance rates of biofilm strains vs. non-
biofilm strains were for  Ceftriaxone (82.9%vs.36.8%), ciprofloxacin (80.9%vs. 57.9%), cefotaxime 
(72.4%vs.49.5%), norfloxacin (85.7%vs. 40%) and cotrimoxazol (71.4%vs.45). Least resistant drugs observed 
were nitrofurantoin (40%vs.23.2%), gentamicin (29.5%vs.22.1%), and amikacin (33.3%vs.14.7%).  
 DISCUSSION 
In the current study, biofilm formation was observed among 112/227 (49.3%) isolates, Out of which, 48 
(21.10%) were high, 64 (28.2%) were moderate and 115 (50.7%) were non biofilm producers. The current study 
is in concordance with Maqbool et al.,
22
 who observed 47.5% biofilm forming among bacterial isolates from 
UTI. Hassan et al., 
23
,  Abdagire et al.,
24
 and Soto  
25
 performed  similar studies to detected biofilm forming 
capacity for the uropathogens among patients with catheter associated urinary tract infections, the biofilm 
production was detected in about 50% of the cases, a value also closer to the one obtained in the present study 
(table 4).  
   When the rate of biofilm formation with respect to duration of catheterization of patients was considered, there 
was significant increase in the rate of biofilm formation with longer duration of catheterization in which the 
highest rate was occurred in >7 days duration with rate equal to 92%, followed by 4-7 days duration with rate 
equal to 43%, while with <4 days duration the rate only was 31.9%. This result is similar to that previously 
reported in which the formation of biofilm by urinary pathogens on the surface of the catheter and drainage 
system occurs universally with prolonged duration of catheterization
26
. The mechanism of the biofilm forming 
capacity for the uropathogens among patients with catheter associated urinary tract infections can be explained by 
that bacteria invading urinary tract met with potent innate defenses, including neutrophil influx and epithelial 
exfoliation. Bacterial subversion of innate responses involves invasion into bladder superficial cell and bacteria 
matured into biofilm, creating pod-like bulges on the bladder surface. Pods contained bacteria covered in a 
polysaccharide-rich matrix surrounded by a protective shell of uroplakin. Thus, biofilm-like pods explains how 
bladder infections can persist in the face of healthy host defense
27
. 
   One of the  aim of this study was to identify the association between biofilm production and uropathogens strains. 
The maximum biofilm production was seen in E. coli where 63 out of the 105 isolates (61%) showed biofilm 
production followed by Klebsiella spp. (57.1%) and Pseudomonas spp. (37.0%). This is in accordance with 
Niveditha et al.,
28
 who also observed  E.coli (42%) as the most common biofilm producers, while Deotale et al.
29
 
reported biofilm production was more frequent by K.pneumoniae  (76%) comparing with lower rate (50%) of 
E.coli which is different from the present study. 
Considering risk factors for biofilm producing as previous incidence of UTI, catheterization, a prolonged 
duration of catheterization (≥7 days), Diabetic mellitus and the age group > 60 years which they had approved to 
increase the propensity of microorganisms to form biofilms in the urinary tract
30
. In the current study, the 
incidence of biofilm producing increased with increase in the age of the patient, maximum incidence was from 
>60 years age group which had 50  biofilm producing cases out of 65 patients (76.9%) . Also when association 
was seen between age >60 years and age <45 years considering both males and females together, it was found to 
be statistically significant (P value <0.0001). The odd ratio was 5.4 which displayed that those aged >60 years 
possess the risk of developing biofilm 5.4 times more than those who aged <60 years. These  results are similar 
to Trautner et al.
30
 and Soto
25
 who have demonstrated a positive correlation among catheterization, old patients 
  
 
and biofilm formation 
25,30
 in addition to old ages they suggested that a significant history of UTI is a major 
indicator for the recurrence of UTI due to biofilm formation.  
  In present study incidence of biofilm producing among diabetics was higher (70%). After multivariate analysis 
diabetes was found to have significant association with biofilm formation (p<0.0001) The odd ratio was 3.5 
which displayed that those with the diabetic possess the risk of developing biofilm 3.5 times more than those 
who non diabetic. This is in agreement with Pramodhini et al.
31
 who reported that the incidence of biofilm 
producing among diabetics was higher than that among non-diabetics patients with indwelling catheter
31
. 
  The crucial aim of this study was identify the association between biofilm production and anti-biogram 
susceptibility of uropathogens strains isolated from the study patients. The antibiotic resistance was significantly 
higher among biofilm producers than among non biofilm producers. This finding was comparable to the studies 
conducted by Pramodhini et al., 
31
; Maqbool et al.,
22
; and Tayal et al.,
32
 in which antibiotic resistance was 
significantly higher among biofilm producers than among non biofilm producers.  The degree of antibiotic 
resistance may be higher among biofilm producers than in non-biofilm isolates in the present study and previous 
studies may be due to bacterial biofilms with long term persistence of organism in various environments, 
decreased bacterial growth rate in a biofilm, expression of resistance genes, and restricted penetration of 
antibiotics into biofilm. Furthermore, proximity of cells within a biofilm can facilitate a plasmid exchange and 
hence enhance the spread of antimicrobial resistance as it had been described by Abdagire et al.,
24
. 
The present study showed that the most effective antibiotics against biofilm producing Gram negative 
isolates from UTIs were found to be imipenem and for Gram positive isolates was vancomycin. This is in 
agreement with Tayal et al., 
32
 who found that the most effective antibiotics against Gram-negative bacteria were 
imipenem and amikacin and for Gram positive isolates was vancomycin.  In the current study Imipenem, is the 
antimicrobial agent that is effective against both Gram positive and Gram negative organisms while, 
nitrofurantoin was not effective against both Gram positive and Gram negative organisms in which the resistant 
rate was 40% for biofilm producing bacteria (tables 7,8). These results are different from Panda et al.
33 
study in 
which they noted in 2016 that nitrofurantoin was effective against both Gram positive and Gram negative biofilm 
producing bacteria 
33
. 
In the present study the investigated biofilm strains displayed relatively high resistance against tested 
antibiotics than non biofilm producers. Resistance to five antibiotics  such as Ceftriaxone (82.9%vs.36.8%), 
ciprofloxacin (80.9% vs. 57.9%), cefotaxime (72.4% vs.49.5%), norfloxacin (85.7% vs. 40%) and cotrimoxazol 
(71.4%, vs.45%) was comparatively higher among biofilm producers than non-biofilm producers. Least resistant 
drugs observed were nitrofurantoin (40%vs.23.2%), gentamicin (29.5%vs.22.1%), and amikacin (33.3% vs. 
14.7%) (table 7, 8). Similar results were reported by Chatterjee et al.
34
 in which the studied biofilm strains 
displayed relatively high resistance against previously tested antibiotics than non biofilm producers.  
CONCLUSION 
 High antimicrobial resistance was observed in biofilm producers than non-biofilm producers. Of recommended 
antimicrobial therapies for CAUTIs, ampicillin and amoxicillin-clavulanate were the least active antibiotics, 
whereas  imipenem and amikacin were found as the most effectual for gram-negative biofilm producer. 
Likewise, penicillin and erythromycin were the least active antibiotics, whereas vancomycin, and rifampicin 
were found as the most effective antibiotic for Gram-positive biofilm producers.  
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Table1: The age and sex distribution of patients with indwelling catheters. 
 
 
Total 
Sex 
 
Age group in years Female Male 
% NO. % NO. % NO.  
5.7 13 38.5 5 61.5 8 1-15 
20.3 46 45.7 21 54.3 25 16-30 
22.9 52 53.8 28 46.2 24 31-45 
22.5 51 45.1 23 54.9 28 46-60 
28.6 65 44.6 29 55.4 36 > 60 
100 227 46.7 106 53.2 121 Total 
  
  
Table 2: Distribution of uropathogens from catheter urine samples. 
Bacteria Number Percentage % 
Escherichia coli 105 46.3 
Klebsiella pneumoniae 42 18.5 
Pseudomonas aeruginosa 27 11.9 
Proteus mirabilis 16 7.0 
Coagulase negative Staphylococci 13 5.7 
Enterobacter spp. 10 4.4 
Staphylococcus aureus 11 4.8 
Enterococcus faecalis 3 1.3 
Total 227 100.0 
 
 
  
 
Table 3: The associated Odds ratio (OR) of uropathogens in ability to produce biofilms in patients with 
indwelling catheters 
* Staphylococcus aureus was used as reference strain of biofilm formation in which it show the lowest rate of 
biofilm producing.  
 
P 
 
X
2
 
 
CI 
 
OR 
Non biofilm 
producer 
Biofilm  
producer  
Bacteria 
% No. % No. 
 
0.002 
 
9.5 
 
1.6-61.3 
 
8.6 
 
40 
 
42 
 
60 
 
63 
E. coli   n= 105 
 
0.002 
 
9.3 
 
1.6-79 
 
10.1 
 
42.9 
 
18 
 
57.1 
 
24 
K. pneumonia n= 42 
 
0.02 
 
5.3 
 
1.0-54 
 
6.6 
 
63 
 
17 
 
37 
 
10 
P. aeruginosa  n= 27 
 
0.28 
 
1.17 
 
0.3-25.9 
 
2.7 
 
68.8 
 
11 
 
31.2 
 
5 
P. mirabilis   n= 16 
 
0.52 
 
0.4 
 
0.2-23 
 
1.9 
 
69.2 
 
9 
 
30.8 
 
4 
Coagulase negative 
Staphylococci       n= 13 
 
0.64 
 
0.22 
 
0-154 
 
0.1 
 
70 
 
7 
 
30 
 
3 
Enterobacter spp.           
n= 10 
 
0.47 
 
0.5 
 
0.21-21.4 
 
2 
 
66.7 
 
2 
 
33.3 
 
1 
E.  faecalis  
n= 3 
    81.8 9 18.2 2 
S. aureus
 *
  
 n= 11
 
  
 
Table 4: Biofilm detection by TCA method among patients with indwelling catheters. 
 
 
 
Bacteria 
Biofilm detection by TCA  
 
Total 
High* Moderate* Non/weak* 
No. % No. % No. % No. % 
Escherichia coli 29 27.6 34 32.4 42 40.0 105 46.3 
Klebsiella pneumoniae 11 26.2 13 30.9 18 42.9 42 18.5 
Pseudomonas aeruginosa 6 22.2 4 14.8 17 63.0 27 11.9 
Proteus mirabilis 0 0 5 31.2 11 68.8 16 7.0 
Coagulase negative  
Staphylococci 
1 7.7 3 23.1 9 69.2 13 5.7 
Enterobacter spp. 0 0 3 30.0 7 70.0 10 4.4 
Enterococcus faecalis 0 0 1 33.3 2 66.7 3 4.8 
Staphylococcus aureus 1 9.1 1 9.1 9 81.8 11 1.3 
Total 48 21.1 64 28.2 115 50.7 227 100 
 
Table 5: The association between age groups of patients and producing biofilm in catheters. 
 
P 
 
X
2
 
 
CI 
 
OR 
Non biofilm 
producer  
n= 115 
Biofilm  
producer         
n= 112 
 
Age group 
% No. % No. 
0.419 0.65 0.2-2.2 0.36 76.9 10 23.1 3 
1-15 years            
                         
n= 13 
0.016 5.85 0.24- 0.87 0.46 65.4 34 34.6 18 
16-30 years          
     n= 52 
0.373 0.79 0.39-1.43 0.74 60.9 28 39.1 18 
31-45 years          
      n= 46 
0.059 
 
3.84 
 
0.28-1.01 0.53 59.9 28 45.1 23 
46-60 years          
      n= 51 
<0.001 27.7 2.78-10.38 5.4 23.1 15 76.9 50 
>  60 years            
    n= 65 
  
 
 
 
 
Table 6: The associated risk factors of biofilm producing in catheters by bacteria among patients with indwelling 
catheters. 
 
 
Table 7: Antibiotic resistance pattern of Gram negative bacteria. 
 
P value 
Non-biofilm         
producing bacteria 
n=95 
Biofilm producing 
bacteria 
n=105 
Antimicrobial agents 
0.002 14.7% 33.3% Amikacin 
0.009 93.7% 100% Amoxicillin clavulanic acid 
0.067 96.8 100% Ampicillin 
<0.001 66.3% 88.6% Cotrimoxazole 
<0.001 57.9% 80.9% Ciprofloxacin 
0.233 22.1% 29.5% Gentamicin 
<0.001 36.8% 82.9% Ceftriaxone 
0.396 86.3% 81.9% Nalidixic acid 
0.011 23.2% 40% Nitrofurantoin 
 
P value 
 
X
2
 
 
CI 
 
OR 
Non biofilm 
producer 
Biofilm 
 producer  
Risk factor 
% No. % No. 
 
0.211 
 
1.6 
 
0.42-1.21 
 
0.72 
 
54.5 
 
66 
 
45.5 
 
55 
       Sex 
Male 
46.2 49 53.8 57 Female 
 
0.001 
 
9.8 
 
1.3-4.33 
 
2.4 
 
42.6 
60 
 
57.4 
81 Pre- UTI 
 
<0.0001 
 
27.7 
 
2.7-10.9 
 
5.4 
 
23.1 
15 76.9 50 Age group >60 years 
 
<0.0001 
 
43.9 
 
5.5-46.3 
 
15.3 
 
8.0 
4 92.0 46 
Duration of    
catheterization              
   >7 days 
 
<0.0001 
 
15.2 
 
1.8-6.6 
 
3.5 
 
28.8 
17 
 
71.2 
42 Diabetic mellitus 
 
0.33 
 
0.94 
 
0.67-2.99 
 
1.4 
 
43.6 
17 
 
56.4 
22 Renal calculi 
 
0.94 
 
0.006 
 
0.49-1.91 
 
0.97 
 
51.2 
21 
 
48.9 
20 Hypertension 
  
 
<0.001 49.5% 72.4% Cefotaxime 
0.07 0% 8.6% Imipenem 
 
Table 8: Antibiotic resistance pattern of Gram positive bacteria. 
 
 
P value 
Non-biofilm 
producing 
organisms n=20 
Biofilm producing 
organisms 
n=7 
Antimicrobial agents 
0.229 45% 71.4% Co-trimoxazole 
NA 0% 0% Vancomycin 
0.756 90% 85.7% Penicillin 
0.0048 15% 71.4% Gentamycin 
0.414 70% 85.7% Erythromycin 
0.373 25% 42.9% Nitrofurantoin 
0.432 40% 57.1% Norfloxacin 
NA 0 0 Rifampicin 
NA= not applicable  
